Novartis Buys Excellergy for $2B, Boosts Allergy Portfolio

Novartis Acquires Excellergy for Up to $2B, Boosting Anti-Allergy Portfolio and U.S. Presence

Swiss pharmaceutical giant Novartis has agreed to buy California-based biotech firm Excellergy for up to $2 billion, expanding its anti-allergy offerings and strengthening its U.S. market position. The deal, set to close in H2 2026, includes an upfront cash payment and milestone payments.

Excellergys lead candidate, Exl-one eleven, targets food allergies by targeting IgE antibodies, similar to Novartiss top-selling Xolair, which treats allergic asthma and other conditions. However, Xolair now faces competition from biosimilars in European markets due to expired patents.

Early studies suggest Exl-one eleven may outperform current treatments by binding more tightly and clearing IgE faster, but larger human trials are needed to confirm these findings.

This acquisition aligns with Novartiss broader strategy, which includes a $23 billion investment over five years to develop U.S. research and manufacturing sites in states like California, Indiana, and New Jersey.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
[email protected]

This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].

View sources & latest updates:
https://sources.thednn.ai/69024a0ae77e3b4f